Do low EPA and a high AA:EPA ratio reinforce inflammatory lipid signaling?

Genetic and enzymatic determinants of lipid signaling

• Genetic constraints: Polymorphisms in the fatty acid desaturase (FADS1/FADS2) gene cluster impair the conversion of precursor alpha-linolenic acid (ALA) to eicosapentaenoic acid (EPA), depleting the systemic EPA pool.
• Substrate restriction: Low EPA status limits the substrate available to cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 enzymes. This directly impairs the synthesis of EPA-derived specialized pro-resolving mediators (SPMs), such as E-series resolvins (RvE1 and RvE2).

Competitive lipid mediator dynamics and inflammation

• Enzymatic competition: Because arachidonic acid (AA) and EPA compete directly for the same metabolic machinery, an elevated AA:EPA ratio biophysically biases metabolic flux toward AA-derived eicosanoids.
• Pro-inflammatory bias: This competitive shift drives the synthesis of highly active pro-inflammatory mediators, such as prostaglandin E2 (PGE2) and leukotriene B4 (LTB4), rather than less-inflammatory EPA-derived counterparts.
• Self-reinforcing loop: Active inflammatory states trigger phospholipase A2 (PLA2) to release membrane-bound AA and upregulate COX-2 and 5-LOX. Without sufficient EPA to facilitate lipid mediator class switching, this pathway unchecked maintains pro-inflammatory signaling.

Bottom line

• Genetic variations in the FADS pathway decrease systemic EPA and raise the AA:EPA ratio, biochemically shifting enzyme competition to favor pro-inflammatory AA eicosanoids (PGE2, LTB4) while restricting resolving EPA-derived resolvins (RvE1, RvE2)—a cycle further reinforced by inflammation-induced AA release.